BOOK
2017 Intravenous Medications - E-Book
Betty L. Gahart | Adrienne R. Nazareno | Meghan Ortega, RN
(2016)
Additional Information
Book Details
Abstract
Safely and effectively administer more than 400 intravenous drugs with the expert guidance of this #1 IV drug handbook! Now in its 33rd edition, Gahart’s 2017 Intravenous Medications: A Handbook for Nurses and Health Professionals continues to be a trusted resource its accuracy, quick-reference format, and comprehensive coverage of IV drugs. Each drug monograph includes the drug’s generic name, trade name(s), drug category, pH, dosages and dose adjustments, dilution, incompatibilities, rate of administration, actions, indications and uses, contraindications, precautions, drug/lab interactions, side effects, and antidote. It’s all of the information you will need for the safe administration of IV drugs — nothing more and nothing less.
- UNIQUE! Annual publication ensures that information includes the most recently approved IV drugs, as well as updated information on existing drugs.
- 40-year history of impeccable accuracy reinforces the importance of safe IV drug administration.
- UNIQUE! Time-tested, easy-to-use page layout keeps all dosage information for each drug on either a single page or a two-page spread to prevent hand contamination by having to turn a page.
- Black Box Warnings and key content are highlighted to make locating key information fast and easy.
- Special circumstances highlighted in blue-screened text call attention to important circumstances that may not warrant black box warnings.
- Convenient, alphabetical format organizes all drug monographs by generic name, allowing you to find any drug in seconds.
- Dilution and dosage charts within monographs provide quick access to essential clinical information.
- Age-specific dosage variances are highlighted for geriatric, pediatric, infant, and neonatal patients.
- NEW! 15 new drug monographs provide current, clinically relevant drug information for new IV drugs recently approved by the FDA.
- NEW! Updated drug monographs throughout reflect the latest changes in IV drug therapy.
- NEW! Do Not Confuse With information is added at the top of each applicable monograph to enhance medication safety, and the Evolve companion website includes a link to the ISMP list of Do Not Confuse drug names.
- NEW! Reorganized drug side effects reflect the latest information on frequency, seriousness, and other important considerations.
- NEW! Alphabetical thumb tabs on the left-hand pages make it easier to look up drug monographs.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front cover | Cover | ||
| General dilution chart (Gm to mg) | ifc1 | ||
| General dilution chart (mg to mcg) | i | ||
| Evolve | ii | ||
| How to use this book | iii | ||
| Step 1 | iii | ||
| Step 2 | iii | ||
| That’s it! | iii | ||
| Develop the “look it up” habit. | iii | ||
| Front matter | v | ||
| Intravenous medications a handbook for nurses and health professionals | v | ||
| Copyright page | vi | ||
| Nursing and pharmacology consultants | vii | ||
| Reviewers | vii | ||
| Dedication | viii | ||
| Preface | ix | ||
| Table of contents | xii | ||
| Format and content of intravenous medications | xiv | ||
| Compatibilities | xv | ||
| Rate of administration: | xvi | ||
| Actions: | xvi | ||
| Indications and uses: | xvi | ||
| Contraindications: | xvi | ||
| Precautions: | xvi | ||
| Monitor: | xvii | ||
| Patient education: | xvii | ||
| Maternal/child: | xvii | ||
| Elderly: | xvii | ||
| Drug/lab interactions: | xvii | ||
| Side effects: | xvii | ||
| Post-marketing: | xvii | ||
| Antidote: | xvii | ||
| Key to abbreviations | xviii | ||
| Important IV therapy facts | xx | ||
| Usual dose | xx | ||
| Dilution | xx | ||
| Incompatibilities | xxi | ||
| Techniques | xxi | ||
| Rate of administration | xxi | ||
| Patient education | xxi | ||
| Side effects | xxi | ||
| Resources | xxii | ||
| Publications | xxii | ||
| Website resources | xxii | ||
| Generic drugs: A | e1 | ||
| A | 1 | ||
| Abatacept | 1 | ||
| Usual dose | 1 | ||
| Pediatric dose | 1 | ||
| Dose adjustments | 1 | ||
| Dilution | 1 | ||
| Compatibility | 2 | ||
| Rate of administration | 2 | ||
| Actions | 2 | ||
| Indications and uses | 2 | ||
| Contraindications | 2 | ||
| Precautions | 2 | ||
| Drug/lab interactions | 3 | ||
| Side effects | 3 | ||
| Antidote | 4 | ||
| Abciximab | 4 | ||
| Usual dose | 4 | ||
| Dilution | 4 | ||
| Compatibility | 5 | ||
| Rate of administration | 5 | ||
| Actions | 5 | ||
| Indications and uses | 5 | ||
| Contraindications | 5 | ||
| Precautions | 5 | ||
| Drug/lab interactions | 7 | ||
| Side effects | 7 | ||
| Antidote | 7 | ||
| Acetaminophen | 8 | ||
| Usual dose | 8 | ||
| Pediatric dose | 8 | ||
| Dose adjustments | 8 | ||
| Dilution | 8 | ||
| Compatibility | 9 | ||
| Rate of administration | 9 | ||
| Actions | 9 | ||
| Indications and uses | 9 | ||
| Contraindications | 9 | ||
| Precautions | 9 | ||
| Drug/lab interactions | 10 | ||
| Side effects | 10 | ||
| Antidote | 10 | ||
| Acetazolamide sodium | 11 | ||
| Usual dose | 11 | ||
| Pediatric dose | 11 | ||
| Dose adjustments | 11 | ||
| Dilution | 11 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 11 | ||
| Rate of administration | 11 | ||
| Actions | 11 | ||
| Indications and uses | 12 | ||
| Contraindications | 12 | ||
| Precautions | 12 | ||
| Drug/lab interactions | 12 | ||
| Side effects | 12 | ||
| Antidote | 12 | ||
| Acetylcysteine injection* | 13 | ||
| Usual dose (adult and pediatric) | 13 | ||
| Dose adjustments | 14 | ||
| Dilution | 14 | ||
| Compatibility | 15 | ||
| Rate of administration | 15 | ||
| Actions | 15 | ||
| Indications and uses | 15 | ||
| Contraindications | 15 | ||
| Precautions | 15 | ||
| Drug/lab interactions | 16 | ||
| Side effects | 16 | ||
| Antidote | 16 | ||
| Acyclovir | 17 | ||
| Usual dose | 17 | ||
| Pediatric dose | 17 | ||
| Neonatal dose | 17 | ||
| Dose adjustments | 17 | ||
| Dilution | 17 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 18 | ||
| Rate of administration | 18 | ||
| Actions | 18 | ||
| Indications and uses | 18 | ||
| Contraindications | 18 | ||
| Precautions | 19 | ||
| Drug/lab interactions | 19 | ||
| Side effects | 19 | ||
| Antidote | 20 | ||
| Adenosine | 20 | ||
| Usual dose | 20 | ||
| Pediatric dose | 20 | ||
| Dose adjustments | 20 | ||
| Dilution | 20 | ||
| Compatibility | 21 | ||
| Rate of administration | 21 | ||
| Actions | 21 | ||
| Indications and uses | 21 | ||
| Contraindications | 21 | ||
| Precautions | 21 | ||
| Drug/lab interactions | 22 | ||
| Side effects | 23 | ||
| Antidote | 23 | ||
| Ado-trastuzumab emtansine | 24 | ||
| Usual dose | 24 | ||
| Dose adjustments | 24 | ||
| Dilution | 25 | ||
| Compatibility | 26 | ||
| Rate of administration | 26 | ||
| Actions | 26 | ||
| Indications and uses | 26 | ||
| Contraindications | 26 | ||
| Precautions | 26 | ||
| Drug/lab interactions | 27 | ||
| Side effects | 28 | ||
| Antidote | 28 | ||
| Albumin (human) | 29 | ||
| Usual dose | 29 | ||
| Pediatric dose | 29 | ||
| Dilution | 30 | ||
| Compatibility | 30 | ||
| Rate of administration | 30 | ||
| Actions | 30 | ||
| Indications and uses | 30 | ||
| Contraindications | 31 | ||
| Precautions | 31 | ||
| Drug/lab interactions | 31 | ||
| Side effects | 31 | ||
| Antidote | 31 | ||
| Aldesleukin | 32 | ||
| Usual dose\t(international units [IU]) | 32 | ||
| Dose adjustments | 32 | ||
| Dilution\t(international units [IU]) | 33 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 33 | ||
| Rate of administration | 34 | ||
| Actions | 34 | ||
| Indications and uses | 34 | ||
| Contraindications | 34 | ||
| Precautions | 35 | ||
| Drug/lab interactions | 37 | ||
| Side effects | 37 | ||
| Antidote | 38 | ||
| Alemtuzumab | 39 | ||
| Usual dose | 39 | ||
| Campath | 39 | ||
| Generic drugs: B | e2 | ||
| B | 156 | ||
| Basiliximab | 156 | ||
| Usual dose | 156 | ||
| Pediatric dose | 156 | ||
| Dose adjustments | 156 | ||
| Dilution | 156 | ||
| Compatibility | 156 | ||
| Rate of administration | 156 | ||
| Actions | 156 | ||
| Indications and uses | 157 | ||
| Contraindications | 157 | ||
| Precautions | 157 | ||
| Drug/lab interactions | 157 | ||
| Side effects | 157 | ||
| Antidote | 158 | ||
| Belatacept | 158 | ||
| Usual dose | 158 | ||
| Dose adjustments | 159 | ||
| Dilution | 159 | ||
| Compatibility | 160 | ||
| Rate of administration | 160 | ||
| Actions | 160 | ||
| Indications and uses | 160 | ||
| Contraindications | 160 | ||
| Precautions | 160 | ||
| Drug/lab interactions | 161 | ||
| Side effects | 161 | ||
| Antidote | 162 | ||
| Belimumab | 162 | ||
| Usual dose | 162 | ||
| Dilution | 162 | ||
| Compatibility | 162 | ||
| Rate of administration | 162 | ||
| Actions | 162 | ||
| Indications and uses | 163 | ||
| Contraindications | 163 | ||
| Precautions | 163 | ||
| Drug/lab interactions | 164 | ||
| Side effects | 164 | ||
| Antidote | 164 | ||
| Belinostat | 165 | ||
| Usual dose | 165 | ||
| Dose adjustments | 165 | ||
| Dilution | 165 | ||
| Compatibility | 165 | ||
| Rate of administration | 165 | ||
| Actions | 165 | ||
| Indications and uses | 166 | ||
| Contraindications | 166 | ||
| Precautions | 166 | ||
| Drug/lab interactions | 166 | ||
| Side effects | 167 | ||
| Antidote | 167 | ||
| Bendamustine hydrochloride | 167 | ||
| Usual dose | 167 | ||
| Dose adjustments | 167 | ||
| Dilution | 168 | ||
| Compatibility | 169 | ||
| Rate of administration | 169 | ||
| Actions | 169 | ||
| Indications and uses | 169 | ||
| Contraindications | 169 | ||
| Precautions | 169 | ||
| Drug/lab interactions | 171 | ||
| Side effects | 171 | ||
| Antidote | 171 | ||
| Bevacizumab | 172 | ||
| Usual dose | 172 | ||
| Dose adjustments | 172 | ||
| Dilution | 172 | ||
| Compatibility | 173 | ||
| Rate of administration | 173 | ||
| Actions | 173 | ||
| Indications and uses | 173 | ||
| Contraindications | 173 | ||
| Precautions | 174 | ||
| Drug/lab interactions | 175 | ||
| Side effects | 176 | ||
| Antidote | 176 | ||
| Bivalirudin | 177 | ||
| Usual dose | 177 | ||
| For patients who do not have heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syn ... | 177 | ||
| Generic drugs: C | e3 | ||
| C | 212 | ||
| C1 esterase inhibitor (human or recombinant) | 212 | ||
| Usual dose\t(international units [IU]) | 212 | ||
| D | e4 | ||
| Dacarbazine | 364 | ||
| Usual dose | 364 | ||
| Dose adjustments | 364 | ||
| Dilution | 364 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 364 | ||
| Rate of administration | 364 | ||
| Actions | 364 | ||
| Indications and uses | 364 | ||
| Contraindications | 364 | ||
| Precautions | 364 | ||
| Drug/lab interactions | 365 | ||
| Side effects | 365 | ||
| Antidote | 365 | ||
| Dactinomycin | 366 | ||
| Usual dose | 366 | ||
| Pediatric dose | 366 | ||
| Dose adjustments | 366 | ||
| Dilution | 366 | ||
| Compatibility | 366 | ||
| Rate of administration | 367 | ||
| Actions | 367 | ||
| Indications and uses | 367 | ||
| Contraindications | 367 | ||
| Precautions | 367 | ||
| Drug/lab interactions | 368 | ||
| Side effects | 368 | ||
| Antidote | 368 | ||
| Dalbavancin | 369 | ||
| Usual dose | 369 | ||
| Dose adjustments | 369 | ||
| Dilution | 369 | ||
| Compatibility | 369 | ||
| Rate of administration | 369 | ||
| Actions | 370 | ||
| Indications and uses | 370 | ||
| Contraindications | 370 | ||
| Precautions | 370 | ||
| Drug/lab interactions | 370 | ||
| Side effects | 371 | ||
| Antidote | 371 | ||
| Dantrolene sodium | 372 | ||
| Usual dose | 372 | ||
| Pediatric dose | 372 | ||
| Dose adjustments | 372 | ||
| Dilution | 372 | ||
| Compatibility | 372 | ||
| Rate of administration | 373 | ||
| Actions | 373 | ||
| Indications and uses | 373 | ||
| Contraindications | 373 | ||
| Precautions | 373 | ||
| Drug/lab interactions | 374 | ||
| Side effects | 374 | ||
| Antidote | 374 | ||
| Daptomycin | 374 | ||
| Usual dose | 374 | ||
| Dose adjustments | 374 | ||
| Dilution | 374 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 375 | ||
| Rate of administration | 375 | ||
| Actions | 375 | ||
| Indications and uses | 375 | ||
| Contraindications | 375 | ||
| Precautions | 375 | ||
| Drug/lab interactions | 376 | ||
| Side effects | 377 | ||
| Antidote | 377 | ||
| Daratumumab | 378 | ||
| Usual dose | 378 | ||
| Dose adjustments | 378 | ||
| Dilution | 378 | ||
| Compatibility | 379 | ||
| Rate of administration | 379 | ||
| Actions | 379 | ||
| Indications and uses | 379 | ||
| Contraindications | 379 | ||
| Precautions | 379 | ||
| Drug/lab interactions | 380 | ||
| Side effects | 380 | ||
| Antidote | 381 | ||
| Darbepoetin alfa | 381 | ||
| Usual dose | 381 | ||
| Pediatric dose | 382 | ||
| Dose adjustments | 382 | ||
| Dilution | 383 | ||
| Compatibility | 383 | ||
| Rate of administration | 383 | ||
| Actions | 383 | ||
| Indications and uses | 384 | ||
| Contraindications | 384 | ||
| Precautions | 384 | ||
| Drug/lab interactions | 386 | ||
| Side effects | 386 | ||
| Antidote | 386 | ||
| Daunorubicin hydrochloride ■ daunorubicin citrate liposomal injection | 387 | ||
| Usual dose | 387 | ||
| Generic drugs: E | e5 | ||
| E | 485 | ||
| Eculizumab | 485 | ||
| Usual dose | 485 | ||
| Pediatric dose | 485 | ||
| Dose adjustments | 485 | ||
| Dilution | 486 | ||
| Compatibility | 486 | ||
| Rate of administration | 486 | ||
| Actions | 486 | ||
| Indications and uses | 487 | ||
| Contraindications | 487 | ||
| Precautions | 487 | ||
| Drug/lab interactions | 488 | ||
| Side effects | 488 | ||
| Antidote | 489 | ||
| Edetate calcium disodium | 489 | ||
| Usual dose | 489 | ||
| Dose adjustments | 489 | ||
| Dilution | 490 | ||
| Compatibility | 490 | ||
| Rate of administration | 490 | ||
| Actions | 490 | ||
| Indications and uses | 490 | ||
| Contraindications | 490 | ||
| Precautions | 490 | ||
| Drug/lab interactions | 491 | ||
| Side effects | 491 | ||
| Antidote | 491 | ||
| Edetate disodium | 492 | ||
| Usual dose | 492 | ||
| Pediatric dose | 492 | ||
| Dose adjustments | 492 | ||
| Dilution | 492 | ||
| Compatibility | 492 | ||
| Rate of administration | 492 | ||
| Actions | 492 | ||
| Indications and uses | 492 | ||
| Contraindications | 492 | ||
| Precautions | 492 | ||
| Drug/lab interactions | 493 | ||
| Side effects | 493 | ||
| Antidote | 493 | ||
| Edrophonium chloride | 494 | ||
| Usual dose | 494 | ||
| Pediatric dose | 494 | ||
| Dose adjustments | 494 | ||
| Dilution | 494 | ||
| Compatibility | 494 | ||
| Rate of administration | 495 | ||
| Actions | 495 | ||
| Indications and uses | 495 | ||
| Contraindications | 495 | ||
| Precautions | 495 | ||
| Drug/lab interactions | 495 | ||
| Side effects | 495 | ||
| Antidote | 496 | ||
| Elotuzumab | 496 | ||
| Usual dose | 496 | ||
| Dose adjustments | 496 | ||
| Dilution | 497 | ||
| Compatibility | 497 | ||
| Rate of administration | 497 | ||
| Actions | 498 | ||
| Indications and uses | 498 | ||
| Contraindications | 498 | ||
| Precautions | 498 | ||
| Drug/lab interactions | 499 | ||
| Side effects | 499 | ||
| Antidote | 499 | ||
| Enalaprilat | 500 | ||
| Usual dose | 500 | ||
| Pediatric dose | 500 | ||
| Dose adjustments | 500 | ||
| Dilution | 500 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 500 | ||
| Rate of administration | 501 | ||
| Actions | 501 | ||
| Indications and uses | 501 | ||
| Contraindications | 501 | ||
| Precautions | 501 | ||
| Drug/lab interactions | 502 | ||
| Side effects | 503 | ||
| Antidote | 503 | ||
| Epinephrine hydrochloride | 504 | ||
| Usual dose | 504 | ||
| Pediatric dose | 504 | ||
| Dose adjustments | 505 | ||
| Dilution | 505 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 505 | ||
| Rate of administration | 506 | ||
| Actions | 506 | ||
| Indications and uses | 506 | ||
| Contraindications | 506 | ||
| Precautions | 506 | ||
| Drug/lab interactions | 507 | ||
| Side effects | 507 | ||
| Antidote | 507 | ||
| Epirubicin hydrochloride | 508 | ||
| Usual dose | 508 | ||
| Ellence | 508 | ||
| Pharmorubicin PFS | 508 | ||
| Metastatic breast cancer: | 508 | ||
| Generic drugs: F | e6 | ||
| F | 552 | ||
| Factor IX (human) ■ factor IX complex (human) | 552 | ||
| Usual dose\t(international units [IU]) | 552 | ||
| All formulations | 552 | ||
| Minor hemorrhage: | 552 | ||
| Major trauma or surgery: | 552 | ||
| Dental extraction: | 552 | ||
| Prophylaxis: | 552 | ||
| Factor IX complex | 552 | ||
| Reversal of coumarin effect: | 552 | ||
| Dilution | 552 | ||
| Compatibility | 553 | ||
| Rate of administration | 553 | ||
| Actions | 553 | ||
| Indications and uses | 553 | ||
| Contraindications | 553 | ||
| Precautions | 553 | ||
| Drug/lab interactions | 554 | ||
| Side effects | 554 | ||
| Antidote | 554 | ||
| Factor IX (recombinant) | 555 | ||
| Usual dose\t(international units [IU]) | 555 | ||
| Dose adjustments | 558 | ||
| Dilution | 558 | ||
| Compatibility | 558 | ||
| Rate of administration | 559 | ||
| Actions | 559 | ||
| Indications and uses | 559 | ||
| Contraindications | 559 | ||
| Precautions | 559 | ||
| Drug/lab interactions | 560 | ||
| Side effects | 560 | ||
| Antidote | 561 | ||
| Factor XIII concentrate (human) | 561 | ||
| Usual dose\t(international units [IU]) | 561 | ||
| Dose adjustments | 561 | ||
| Dilution | 561 | ||
| Compatibility | 562 | ||
| Rate of administration | 562 | ||
| Actions | 562 | ||
| Indications and uses | 562 | ||
| Contraindications | 562 | ||
| Precautions | 562 | ||
| Drug/lab interactions | 563 | ||
| Side effects | 563 | ||
| Antidote | 563 | ||
| Famotidine | 564 | ||
| Usual dose | 564 | ||
| Pediatric dose | 564 | ||
| Dose adjustments | 564 | ||
| Dilution | 564 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 564 | ||
| Rate of administration | 565 | ||
| Actions | 565 | ||
| Indications and uses | 565 | ||
| Contraindications | 565 | ||
| Precautions | 565 | ||
| Drug/lab interactions | 565 | ||
| Side effects | 566 | ||
| Antidote | 566 | ||
| Fat emulsion, intravenous* | 566 | ||
| Usual dose | 566 | ||
| Pediatric dose | 566 | ||
| Dose adjustments | 567 | ||
| Dilution | 567 | ||
| Compatibility | 567 | ||
| Rate of administration | 567 | ||
| Actions | 568 | ||
| Indications and uses | 568 | ||
| Contraindications | 568 | ||
| Precautions | 568 | ||
| Drug/lab interactions | 569 | ||
| Side effects | 569 | ||
| Antidote | 569 | ||
| Fenoldopam mesylate | 570 | ||
| Usual dose | 570 | ||
| Pediatric dose | 570 | ||
| Dose adjustments | 570 | ||
| Dilution | 570 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 570 | ||
| Rate of administration | 571 | ||
| Actions | 571 | ||
| Indications and uses | 571 | ||
| Contraindications | 571 | ||
| Precautions | 571 | ||
| Drug/lab interactions | 572 | ||
| Side effects | 572 | ||
| Antidote | 572 | ||
| Fentanyl citrate | 573 | ||
| Usual dose | 573 | ||
| Pediatric dose | 573 | ||
| Dose adjustments | 573 | ||
| Dilution | 573 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 573 | ||
| Rate of administration | 574 | ||
| Actions | 574 | ||
| Indications and uses | 574 | ||
| Contraindications | 574 | ||
| Precautions | 574 | ||
| Drug/lab interactions | 575 | ||
| Side effects | 576 | ||
| Antidote | 576 | ||
| Ferric carboxymaltose injection | 577 | ||
| Usual dose | 577 | ||
| Dilution | 577 | ||
| Compatibility | 577 | ||
| Rate of administration | 577 | ||
| Actions | 577 | ||
| Indications and uses | 577 | ||
| Contraindications | 577 | ||
| Precautions | 577 | ||
| Drug/lab interactions | 578 | ||
| Side effects | 578 | ||
| Antidote | 578 | ||
| Ferumoxytol | 579 | ||
| Usual dose | 579 | ||
| Dose adjustments | 579 | ||
| Dilution | 579 | ||
| Compatibility | 579 | ||
| Rate of administration | 579 | ||
| Actions | 579 | ||
| Indications and uses | 579 | ||
| Contraindications | 579 | ||
| Precautions | 579 | ||
| Drug/lab interactions | 580 | ||
| Side effects | 580 | ||
| Antidote | 580 | ||
| Fibrinogen concentrate (human) | 581 | ||
| Usual dose | 581 | ||
| Dilution | 581 | ||
| Compatibility | 581 | ||
| Rate of administration | 581 | ||
| Actions | 581 | ||
| Indications and uses | 581 | ||
| Contraindications | 581 | ||
| Precautions | 581 | ||
| Drug/lab interactions | 582 | ||
| Side effects | 582 | ||
| Antidote | 582 | ||
| Filgrastim ■ filgrastim-sndz* | 583 | ||
| Usual dose | 583 | ||
| Dose adjustments | 583 | ||
| Dilution | 584 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 584 | ||
| Rate of administration | 584 | ||
| Actions | 585 | ||
| Indications and uses | 585 | ||
| Contraindications | 585 | ||
| Precautions | 585 | ||
| Drug/lab interactions | 587 | ||
| Side effects | 587 | ||
| Antidote | 587 | ||
| Fluconazole | 588 | ||
| Usual dose | 588 | ||
| Pediatric dose | 588 | ||
| Neonatal dose | 588 | ||
| Dose adjustments | 588 | ||
| Dilution | 589 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 589 | ||
| Rate of administration | 589 | ||
| Actions | 589 | ||
| Indications and uses | 590 | ||
| Contraindications | 590 | ||
| Precautions | 590 | ||
| Drug/lab interactions | 591 | ||
| Side effects | 592 | ||
| Antidote | 592 | ||
| Fludarabine phosphate | 593 | ||
| Usual dose | 593 | ||
| Pediatric dose | 593 | ||
| Dose adjustments | 593 | ||
| Dilution | 593 | ||
| Compatibility | 593 | ||
| Rate of administration | 594 | ||
| Actions | 594 | ||
| Indications and uses | 594 | ||
| Contraindications | 594 | ||
| Precautions | 594 | ||
| Drug/lab interactions | 595 | ||
| Side effects | 595 | ||
| Antidote | 596 | ||
| Flumazenil | 597 | ||
| Usual dose | 597 | ||
| Pediatric dose | 597 | ||
| Dose adjustments | 597 | ||
| Dilution | 597 | ||
| Compatibility | 597 | ||
| Rate of administration | 597 | ||
| Actions | 598 | ||
| Indications and uses | 598 | ||
| Contraindications | 598 | ||
| Precautions | 598 | ||
| Drug/lab interactions | 599 | ||
| Side effects | 599 | ||
| Antidote | 600 | ||
| Fluorouracil | 600 | ||
| Usual dose | 600 | ||
| Dose adjustments | 600 | ||
| Dilution | 601 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 601 | ||
| Rate of administration | 601 | ||
| Actions | 601 | ||
| Indications and uses | 601 | ||
| Contraindications | 601 | ||
| Precautions | 602 | ||
| Drug/lab interactions | 602 | ||
| Side effects | 602 | ||
| Antidote | 603 | ||
| Folic acid | 603 | ||
| Usual dose | 603 | ||
| Pediatric dose | 603 | ||
| Dose adjustments | 603 | ||
| Dilution | 603 | ||
| Compatibility | 603 | ||
| Rate of administration | 603 | ||
| Actions | 604 | ||
| Indications and uses | 604 | ||
| Contraindications | 604 | ||
| Precautions | 604 | ||
| Drug/lab interactions | 604 | ||
| Side effects | 604 | ||
| Antidote | 604 | ||
| Fomepizole injection | 605 | ||
| Usual dose | 605 | ||
| Dose adjustments | 605 | ||
| Dilution | 605 | ||
| Compatibility | 606 | ||
| Rate of administration | 606 | ||
| Actions | 606 | ||
| Indications and uses | 606 | ||
| Contraindications | 606 | ||
| Precautions | 606 | ||
| Drug/lab interactions | 607 | ||
| Side effects | 607 | ||
| Antidote | 607 | ||
| Fosaprepitant dimeglumine | 608 | ||
| Usual dose | 608 | ||
| Dose adjustments | 608 | ||
| Dilution | 608 | ||
| Compatibility | 608 | ||
| Rate of administration | 609 | ||
| Actions | 609 | ||
| Indications and uses | 609 | ||
| Contraindications | 609 | ||
| Precautions | 609 | ||
| Drug/lab interactions | 609 | ||
| Side effects | 610 | ||
| Antidote | 610 | ||
| Foscarnet sodium | 611 | ||
| Usual dose | 611 | ||
| Dose adjustments | 611 | ||
| Dilution | 612 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 612 | ||
| Rate of administration | 612 | ||
| Actions | 613 | ||
| Indications and uses | 613 | ||
| Contraindications | 613 | ||
| Precautions | 613 | ||
| Drug/lab interactions | 614 | ||
| Side effects | 614 | ||
| Antidote | 615 | ||
| Fosphenytoin sodium | 616 | ||
| Usual dose | 616 | ||
| Pediatric dose | 616 | ||
| Dose adjustments | 616 | ||
| Dilution | 616 | ||
| Compatibility | 616 | ||
| Rate of administration | 617 | ||
| Actions | 617 | ||
| Indications and uses | 617 | ||
| Contraindications | 617 | ||
| Precautions | 617 | ||
| Drug/lab interactions | 619 | ||
| Side effects | 620 | ||
| Antidote | 620 | ||
| Furosemide | 621 | ||
| Usual dose | 621 | ||
| Pediatric dose | 621 | ||
| Neonatal dose | 621 | ||
| Dose adjustments | 621 | ||
| Dilution | 621 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 621 | ||
| Rate of administration | 622 | ||
| Actions | 622 | ||
| Indications and uses | 622 | ||
| Contraindications | 622 | ||
| Precautions | 622 | ||
| Drug/lab interactions | 623 | ||
| Side effects | 624 | ||
| Antidote | 624 | ||
| Generic drugs: G | e7 | ||
| Pediatric dose | 625 | ||
| Dose adjustments | 625 | ||
| Dilution | 625 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 626 | ||
| Rate of administration | 626 | ||
| Actions | 626 | ||
| Indications and uses | 626 | ||
| Contraindications | 626 | ||
| Precautions | 626 | ||
| Drug/lab interactions | 627 | ||
| Side effects | 628 | ||
| Antidote | 628 | ||
| Gemcitabine hydrochloride | 628 | ||
| Usual dose | 628 | ||
| Dose adjustments | 629 | ||
| Dilution | 630 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 630 | ||
| Rate of administration | 631 | ||
| Actions | 631 | ||
| Indications and uses | 631 | ||
| Contraindications | 631 | ||
| Precautions | 631 | ||
| Drug/lab interactions | 632 | ||
| Side effects | 633 | ||
| Antidote | 633 | ||
| Gentamicin sulfate | 634 | ||
| Usual dose | 634 | ||
| Pediatric dose | 634 | ||
| Neonatal dose | 634 | ||
| Dose adjustments | 634 | ||
| Dilution | 635 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 635 | ||
| Rate of administration | 636 | ||
| Actions | 636 | ||
| Indications and uses | 636 | ||
| Contraindications | 636 | ||
| Precautions | 637 | ||
| Drug/lab interactions | 637 | ||
| Side effects | 638 | ||
| Antidote | 638 | ||
| Glucagon (rDNA origin) | 639 | ||
| Usual dose | 639 | ||
| Pediatric dose | 639 | ||
| Dose adjustments | 639 | ||
| Dilution | 639 | ||
| Compatibility | 639 | ||
| Rate of administration | 639 | ||
| Actions | 640 | ||
| Indications and uses | 640 | ||
| Contraindications | 640 | ||
| Precautions | 640 | ||
| Drug/lab interactions | 641 | ||
| Side effects | 641 | ||
| Antidote | 641 | ||
| Glucarpidase | 642 | ||
| Usual dose | 642 | ||
| Pediatric dose | 642 | ||
| Dose adjustments | 642 | ||
| Dilution | 642 | ||
| Compatibility | 642 | ||
| Rate of administration | 642 | ||
| Actions | 642 | ||
| Indications and uses | 642 | ||
| Contraindications | 642 | ||
| Precautions | 643 | ||
| Drug/lab interactions | 643 | ||
| Side effects | 643 | ||
| Antidote | 643 | ||
| Glycopyrrolate | 644 | ||
| Usual dose | 644 | ||
| Pediatric dose | 644 | ||
| Dose adjustments | 644 | ||
| Dilution | 644 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 645 | ||
| Rate of administration | 645 | ||
| Actions | 645 | ||
| Indications and uses | 645 | ||
| Contraindications | 645 | ||
| Precautions | 645 | ||
| Drug/lab interactions | 646 | ||
| Side effects | 646 | ||
| Antidote | 646 | ||
| Golimumab | 647 | ||
| Usual dose | 647 | ||
| Dilution | 647 | ||
| Compatibility | 647 | ||
| Rate of administration | 647 | ||
| Actions | 647 | ||
| Indications and uses | 648 | ||
| Contraindications | 648 | ||
| Precautions | 648 | ||
| Drug/lab interactions | 650 | ||
| Side effects | 650 | ||
| Antidote | 650 | ||
| Granisetron hydrochloride | 651 | ||
| Usual dose | 651 | ||
| Pediatric dose | 651 | ||
| Dose adjustments | 651 | ||
| Dilution | 651 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 651 | ||
| Rate of administration | 652 | ||
| Actions | 652 | ||
| Indications and uses | 652 | ||
| Contraindications | 652 | ||
| Precautions | 652 | ||
| Drug/lab interactions | 653 | ||
| Side effects | 653 | ||
| Generic drugs: H | e8 | ||
| H | 654 | ||
| Hemin | 654 | ||
| Usual dose | 654 | ||
| Dilution | 654 | ||
| Compatibility | 654 | ||
| Rate of administration | 654 | ||
| Actions | 654 | ||
| Indications and uses | 654 | ||
| Contraindications | 654 | ||
| Precautions | 654 | ||
| Drug/lab interactions | 655 | ||
| Side effects | 655 | ||
| Antidote | 655 | ||
| Heparin sodium | 655 | ||
| Usual dose | 655 | ||
| Pediatric dose | 656 | ||
| Dose adjustments | 657 | ||
| Dilution | 657 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 657 | ||
| Rate of administration | 658 | ||
| Actions | 658 | ||
| Indications and uses | 659 | ||
| Contraindications | 659 | ||
| Precautions | 659 | ||
| Drug/lab interactions | 660 | ||
| Side effects | 661 | ||
| Antidote | 661 | ||
| Hepatitis B immune globulin intravenous (human) | 662 | ||
| Usual dose\t(international units [IU]) | 662 | ||
| Dose adjustments\t(international units [IU]) | 662 | ||
| Dilution | 662 | ||
| Compatibility | 662 | ||
| Rate of administration | 662 | ||
| Actions | 662 | ||
| Indications and uses | 663 | ||
| Contraindications | 663 | ||
| Precautions | 663 | ||
| Drug/lab interactions | 664 | ||
| Side effects | 664 | ||
| Antidote | 664 | ||
| Hetastarch | 664 | ||
| Usual dose | 664 | ||
| Hespan, hextend | 664 | ||
| Plasma volume expansion: | 664 | ||
| Hespan | 664 | ||
| Leukapheresis: | 664 | ||
| Dose adjustments | 664 | ||
| Dilution | 664 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 665 | ||
| Hespan | 665 | ||
| Additive: | 665 | ||
| Generic drugs: I | e9 | ||
| I | 684 | ||
| Ibandronate sodium | 684 | ||
| Usual dose | 684 | ||
| Dose adjustments | 684 | ||
| Dilution | 684 | ||
| Compatibility | 684 | ||
| Rate of administration | 684 | ||
| Actions | 684 | ||
| Indications and uses | 684 | ||
| Contraindications | 684 | ||
| Precautions | 684 | ||
| Drug/lab interactions | 685 | ||
| Side effects | 686 | ||
| Antidote | 686 | ||
| Ibuprofen | 686 | ||
| Usual dose | 686 | ||
| Pediatric dose | 686 | ||
| Dose adjustments | 686 | ||
| Dilution | 687 | ||
| Compatibility | 687 | ||
| Rate of administration | 687 | ||
| Actions | 687 | ||
| Indications and uses | 687 | ||
| Contraindications | 687 | ||
| Precautions | 687 | ||
| Drug/lab interactions | 688 | ||
| Side effects | 689 | ||
| Antidote | 689 | ||
| Ibuprofen lysine | 690 | ||
| Neonatal dose | 690 | ||
| Dose adjustments | 690 | ||
| Dilution | 690 | ||
| Compatibility | 690 | ||
| Rate of administration | 690 | ||
| Actions | 690 | ||
| Indications and uses | 690 | ||
| Contraindications | 690 | ||
| Precautions | 691 | ||
| Drug/lab interactions | 691 | ||
| Side effects | 691 | ||
| Antidote | 691 | ||
| Ibutilide fumarate | 692 | ||
| Usual dose | 692 | ||
| Dose adjustments | 692 | ||
| Dilution | 692 | ||
| Compatibility | 692 | ||
| Rate of administration | 692 | ||
| Actions | 692 | ||
| Indications and uses | 693 | ||
| Contraindications | 693 | ||
| Precautions | 693 | ||
| Drug/lab interactions | 693 | ||
| Side effects | 693 | ||
| Antidote | 694 | ||
| Idarubicin hydrochloride | 694 | ||
| Usual dose | 694 | ||
| Dose adjustments | 694 | ||
| Dilution | 694 | ||
| Compatibility | 694 | ||
| Rate of administration | 695 | ||
| Actions | 695 | ||
| Indications and uses | 695 | ||
| Contraindications | 695 | ||
| Precautions | 695 | ||
| Drug/lab interactions | 696 | ||
| Side effects | 696 | ||
| Antidote | 696 | ||
| Idarucizumab | 697 | ||
| Usual dose | 697 | ||
| Dose adjustments | 697 | ||
| Dilution | 697 | ||
| Compatibility | 697 | ||
| Rate of administration | 697 | ||
| Actions | 697 | ||
| Indications and uses | 697 | ||
| Contraindications | 698 | ||
| Precautions | 698 | ||
| Drug/lab interactions | 699 | ||
| Side effects | 699 | ||
| Antidote | 699 | ||
| Ifosfamide | 700 | ||
| Usual dose | 700 | ||
| Dose adjustments | 700 | ||
| Dilution | 700 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 700 | ||
| Rate of administration | 700 | ||
| Actions | 701 | ||
| Indications and uses | 701 | ||
| Contraindications | 701 | ||
| Precautions | 701 | ||
| Drug/lab interactions | 703 | ||
| Side effects | 703 | ||
| Antidote | 703 | ||
| Imipenem-cilastatin | 704 | ||
| Usual dose | 704 | ||
| Pediatric dose | 704 | ||
| Dose adjustments | 704 | ||
| Dilution | 705 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 705 | ||
| Rate of administration | 705 | ||
| Actions | 705 | ||
| Indications and uses | 705 | ||
| Contraindications | 705 | ||
| Precautions | 706 | ||
| Drug/lab interactions | 706 | ||
| Side effects | 706 | ||
| Antidote | 707 | ||
| Immune globulin intravenous | 707 | ||
| Usual dose | 707 | ||
| Primary immunodeficiency (PID) diseases | 707 | ||
| Bivigam and gammuplex: | 707 | ||
| Generic drugs: K | e10 | ||
| K | 766 | ||
| Ketorolac tromethamine | 766 | ||
| Usual dose | 766 | ||
| Pediatric dose | 766 | ||
| Dose adjustments | 766 | ||
| Dilution | 766 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 766 | ||
| Rate of administration | 767 | ||
| Actions | 767 | ||
| Indications and uses | 767 | ||
| Contraindications | 767 | ||
| Precautions | 767 | ||
| Drug/lab interactions | 768 | ||
| Side effects | 768 | ||
| Antidote | 768 | ||
| Generic drugs: L | e11 | ||
| L | 769 | ||
| Labetalol hydrochloride | 769 | ||
| Usual dose | 769 | ||
| Dose adjustments | 769 | ||
| Dilution | 769 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 769 | ||
| Rate of administration | 769 | ||
| Actions | 770 | ||
| Indications and uses | 770 | ||
| Contraindications | 770 | ||
| Precautions | 770 | ||
| Drug/lab interactions | 770 | ||
| Side effects | 771 | ||
| Antidote | 771 | ||
| Lacosamide | 772 | ||
| Usual dose | 772 | ||
| Dose adjustments | 772 | ||
| Dilution | 772 | ||
| Compatibility | 773 | ||
| Rate of administration | 773 | ||
| Actions | 773 | ||
| Indications and uses | 773 | ||
| Contraindications | 773 | ||
| Precautions | 773 | ||
| Drug/lab interactions | 774 | ||
| Side effects | 775 | ||
| Antidote | 775 | ||
| Leucovorin calcium | 776 | ||
| Usual dose | 776 | ||
| Dose adjustments | 776 | ||
| Dilution | 776 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 776 | ||
| Rate of administration | 777 | ||
| Actions | 777 | ||
| Indications and uses | 777 | ||
| Contraindications | 777 | ||
| Precautions | 777 | ||
| Drug/lab interactions | 778 | ||
| Side effects | 778 | ||
| Antidote | 778 | ||
| Levetiracetam injection | 778 | ||
| Usual dose | 778 | ||
| Pediatric dose | 778 | ||
| Dose adjustments | 779 | ||
| Dilution | 779 | ||
| Compatibility | 779 | ||
| Rate of administration | 779 | ||
| Actions | 780 | ||
| Indications and uses | 780 | ||
| Contraindications | 780 | ||
| Precautions | 780 | ||
| Drug/lab interactions | 781 | ||
| Side effects | 781 | ||
| Antidote | 781 | ||
| Levofloxacin | 782 | ||
| Usual dose | 782 | ||
| Dose adjustments | 783 | ||
| Dilution | 783 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 783 | ||
| Rate of administration | 784 | ||
| Actions | 784 | ||
| Indications and uses | 784 | ||
| Contraindications | 784 | ||
| Precautions | 784 | ||
| Drug/lab interactions | 786 | ||
| Side effects | 787 | ||
| Antidote | 787 | ||
| Levoleucovorin | 788 | ||
| Usual dose | 788 | ||
| Pediatric dose | 789 | ||
| Dose adjustments | 789 | ||
| Dilution | 789 | ||
| Compatibility | 789 | ||
| Rate of administration | 789 | ||
| Actions | 789 | ||
| Indications and uses | 790 | ||
| Contraindications | 790 | ||
| Precautions | 790 | ||
| Drug/lab interactions | 790 | ||
| Side effects | 791 | ||
| Antidote | 791 | ||
| Levothyroxine sodium | 791 | ||
| Usual dose | 791 | ||
| Pediatric dose | 791 | ||
| Dose adjustments | 791 | ||
| Dilution | 791 | ||
| Compatibility | 792 | ||
| Rate of administration | 792 | ||
| Actions | 792 | ||
| Indications and uses | 792 | ||
| Contraindications | 792 | ||
| Precautions | 792 | ||
| Drug/lab interactions | 793 | ||
| Side effects | 793 | ||
| Antidote | 793 | ||
| Lidocaine hydrochloride | 794 | ||
| Usual dose | 794 | ||
| Pediatric dose | 794 | ||
| Dose adjustments | 794 | ||
| Dilution | 794 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 795 | ||
| Rate of administration | 795 | ||
| Actions | 796 | ||
| Indications and uses | 796 | ||
| Contraindications | 796 | ||
| Precautions | 796 | ||
| Drug/lab interactions | 797 | ||
| Side effects | 797 | ||
| Antidote | 797 | ||
| Linezolid | 798 | ||
| Usual dose | 798 | ||
| Pediatric dose | 798 | ||
| Dose adjustments | 798 | ||
| Dilution | 798 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 799 | ||
| Rate of administration | 799 | ||
| Actions | 799 | ||
| Indications and uses | 800 | ||
| Contraindications | 800 | ||
| Precautions | 800 | ||
| Drug/lab interactions | 802 | ||
| Side effects | 803 | ||
| Antidote | 803 | ||
| Lorazepam | 804 | ||
| Usual dose | 804 | ||
| Pediatric dose | 804 | ||
| Dose adjustments | 804 | ||
| Dilution | 805 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 805 | ||
| Rate of administration | 806 | ||
| Actions | 806 | ||
| Indications and uses | 806 | ||
| Contraindications | 806 | ||
| Precautions | 806 | ||
| Drug/lab interactions | 807 | ||
| Side effects | 807 | ||
| Antidote | 807 | ||
| Lymphocyte immune globulin | 808 | ||
| Usual dose | 808 | ||
| Pediatric dose | 808 | ||
| Dilution | 808 | ||
| Compatibility | 808 | ||
| Rate of administration | 808 | ||
| Actions | 808 | ||
| Indications and uses | 808 | ||
| Contraindications | 808 | ||
| Precautions | 809 | ||
| Drug/lab interactions | 809 | ||
| Side effects | 809 | ||
| Antidote | 809 | ||
| Generic drugs: M | e12 | ||
| M | 810 | ||
| Magnesium sulfate | 810 | ||
| Usual dose | 810 | ||
| Pediatric dose | 810 | ||
| Dose adjustments | 810 | ||
| Dilution | 811 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 811 | ||
| Rate of administration | 811 | ||
| Actions | 811 | ||
| Indications and uses | 811 | ||
| Contraindications | 812 | ||
| Precautions | 812 | ||
| Drug/lab interactions | 813 | ||
| Side effects | 813 | ||
| Antidote | 813 | ||
| Mannitol | 814 | ||
| Usual dose | 814 | ||
| Pediatric dose | 814 | ||
| Dose adjustments | 814 | ||
| Dilution | 815 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 815 | ||
| Rate of administration | 815 | ||
| Actions | 815 | ||
| Indications and uses | 816 | ||
| Contraindications | 816 | ||
| Precautions | 816 | ||
| Drug/lab interactions | 816 | ||
| Side effects | 816 | ||
| Antidote | 817 | ||
| Melphalan hydrochloride | 817 | ||
| Usual dose | 817 | ||
| Pediatric dose | 817 | ||
| Dose adjustments | 817 | ||
| Dilution | 817 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 818 | ||
| Rate of administration | 818 | ||
| Actions | 819 | ||
| Indications and uses | 819 | ||
| Contraindications | 819 | ||
| Precautions | 819 | ||
| Drug/lab interactions | 820 | ||
| Side effects | 820 | ||
| Antidote | 821 | ||
| Meperidine hydrochloride | 821 | ||
| Usual dose | 821 | ||
| Pediatric dose | 821 | ||
| Dose adjustments | 821 | ||
| Dilution | 821 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 821 | ||
| Rate of administration | 822 | ||
| Actions | 822 | ||
| Indications and uses | 822 | ||
| Contraindications | 822 | ||
| Precautions | 822 | ||
| Drug/lab interactions | 823 | ||
| Side effects | 824 | ||
| Antidote | 824 | ||
| Meropenem | 825 | ||
| Usual dose | 825 | ||
| Pediatric dose | 825 | ||
| Dose adjustments | 825 | ||
| Dilution | 826 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 826 | ||
| Rate of administration | 826 | ||
| Actions | 826 | ||
| Indications and uses | 827 | ||
| Contraindications | 827 | ||
| Precautions | 827 | ||
| Drug/lab interactions | 828 | ||
| Side effects | 828 | ||
| Antidote | 828 | ||
| Mesna | 829 | ||
| Usual dose | 829 | ||
| Dose adjustments | 829 | ||
| Dilution | 829 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 829 | ||
| Rate of administration | 829 | ||
| Actions | 830 | ||
| Indications and uses | 830 | ||
| Contraindications | 830 | ||
| Precautions | 830 | ||
| Drug/lab interactions | 830 | ||
| Side effects | 830 | ||
| Antidote | 830 | ||
| Methadone hydrochloride | 831 | ||
| Usual dose | 831 | ||
| Dose adjustments | 832 | ||
| Dilution | 832 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 832 | ||
| Rate of administration | 832 | ||
| Actions | 832 | ||
| Indications and uses | 832 | ||
| Contraindications | 832 | ||
| Precautions | 833 | ||
| Drug/lab interactions | 834 | ||
| Side effects | 835 | ||
| Antidote | 835 | ||
| Methotrexate sodium | 836 | ||
| Usual dose | 836 | ||
| Pediatric dose | 836 | ||
| Dose adjustments | 837 | ||
| Dilution | 837 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 837 | ||
| Rate of administration | 837 | ||
| Actions | 838 | ||
| Indications and uses | 838 | ||
| Contraindications | 838 | ||
| Precautions | 838 | ||
| Drug/lab interactions | 840 | ||
| Side effects | 840 | ||
| Antidote | 841 | ||
| Methylergonovine maleate | 842 | ||
| Usual dose | 842 | ||
| Dilution | 842 | ||
| Compatibility | 842 | ||
| Rate of administration | 842 | ||
| Actions | 842 | ||
| Indications and uses | 842 | ||
| Contraindications | 842 | ||
| Precautions | 842 | ||
| Drug/lab interactions | 843 | ||
| Side effects | 843 | ||
| Antidote | 843 | ||
| Methylprednisolone sodium succinate | 844 | ||
| Usual dose | 844 | ||
| Pediatric dose | 844 | ||
| Dose adjustments | 845 | ||
| Dilution | 845 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 845 | ||
| Rate of administration | 845 | ||
| Actions | 846 | ||
| Indications and uses | 846 | ||
| Contraindications | 846 | ||
| Precautions | 846 | ||
| Drug/lab interactions | 847 | ||
| Side effects | 848 | ||
| Antidote | 848 | ||
| Metoclopramide hydrochloride | 848 | ||
| Usual dose | 848 | ||
| Pediatric dose | 849 | ||
| Dose adjustments | 849 | ||
| Dilution | 849 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 849 | ||
| Rate of administration | 850 | ||
| Actions | 850 | ||
| Indications and uses | 850 | ||
| Contraindications | 850 | ||
| Precautions | 850 | ||
| Drug/lab interactions | 851 | ||
| Side effects | 851 | ||
| Antidote | 851 | ||
| Metoprolol tartrate | 852 | ||
| Usual dose | 852 | ||
| Dose adjustments | 852 | ||
| Dilution | 852 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 852 | ||
| Rate of administration | 852 | ||
| Actions | 852 | ||
| Indications and uses | 852 | ||
| Contraindications | 853 | ||
| Precautions | 853 | ||
| Drug/lab interactions | 853 | ||
| Side effects | 854 | ||
| Antidote | 854 | ||
| Metronidazole hydrochloride | 855 | ||
| Usual dose | 855 | ||
| Pediatric dose | 855 | ||
| Dose adjustments | 855 | ||
| Dilution | 855 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 856 | ||
| Rate of administration | 856 | ||
| Actions | 856 | ||
| Indications and uses | 856 | ||
| Contraindications | 857 | ||
| Precautions | 857 | ||
| Drug/lab interactions | 857 | ||
| Side effects | 858 | ||
| Antidote | 858 | ||
| Micafungin sodium | 858 | ||
| Usual dose | 858 | ||
| Pediatric dose | 858 | ||
| Dose adjustments | 859 | ||
| Dilution | 859 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 859 | ||
| Rate of administration | 859 | ||
| Actions | 860 | ||
| Indications and uses | 860 | ||
| Contraindications | 860 | ||
| Precautions | 860 | ||
| Drug/lab interactions | 861 | ||
| Side effects | 861 | ||
| Antidote | 861 | ||
| Midazolam hydrochloride | 862 | ||
| Usual dose | 862 | ||
| Sedation, anxiolysis (antianxiety), and/or amnesia for short diagnostic, endoscopic, and therapeutic procedures | 862 | ||
| Healthy adults under 60 years of age: | 862 | ||
| Patients over 60 years of age or debilitated or chronically ill patients: | 862 | ||
| Induction of anesthesia before administration of other anesthetic agents and/or maintenance of anesthesia as a component o ... | 862 | ||
| Unpremedicated patients under 55 years of age: | 862 | ||
| Unpremedicated patients over 55 years of age (ASA I or II): | 862 | ||
| Unpremedicated debilitated patients or those with severe systemic disease (ASA III or IV): | 862 | ||
| Patients premedicated with sedatives or narcotics under 55 years of age: | 862 | ||
| Patients premedicated with sedatives or narcotics over 55 years of age (good risk [ASA I & II]): | 862 | ||
| Patients premedicated with sedatives or narcotics who are debilitated or those with severe systemic disease (ASA III or IV): | 862 | ||
| Sedation for anesthesia or treatment in a critical care setting for intubated and mechanically ventilated patients | 863 | ||
| Continuous infusion (concentration 0.5 mg/mL): | 863 | ||
| For maintenance of sedation: | 863 | ||
| Refractory status epilepticus (unlabeled) | 863 | ||
| Pediatric dose | 863 | ||
| Sedation, anxiolysis (antianxiety), and/or amnesia before and during procedures or before anesthesia | 863 | ||
| Nonintubated infants under 6 months of age: | 863 | ||
| Pediatric patients 6 months to 5 years of age: | 863 | ||
| Pediatric patients 6 to 12 years of age: | 863 | ||
| Pediatric patients 12 to 16 years of age: | 863 | ||
| Sedation, anxiolysis, amnesia | 863 | ||
| Intubated pediatric patients in critical care settings: | 863 | ||
| Sedation of intubated neonates in critical care settings | 864 | ||
| Neonates under 32 weeks: | 864 | ||
| Neonates 32 weeks or older: | 864 | ||
| Refractory status epilepticus (unlabeled) | 864 | ||
| Pediatric patients 2 months of age or older: | 864 | ||
| Loading dose: | 864 | ||
| Dose adjustments | 864 | ||
| Dilution | 864 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 864 | ||
| Rate of administration | 865 | ||
| Actions | 865 | ||
| Indications and uses | 865 | ||
| Contraindications | 865 | ||
| Precautions | 865 | ||
| Drug/lab interactions | 866 | ||
| Side effects | 867 | ||
| Antidote | 867 | ||
| Milrinone lactate | 868 | ||
| Usual dose | 868 | ||
| Dose adjustments | 868 | ||
| Dilution | 868 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 869 | ||
| Rate of administration | 869 | ||
| Actions | 869 | ||
| Indications and uses | 870 | ||
| Contraindications | 870 | ||
| Precautions | 870 | ||
| Drug/lab interactions | 870 | ||
| Side effects | 870 | ||
| Antidote | 871 | ||
| Mitomycin | 871 | ||
| Usual dose | 871 | ||
| Dose adjustments | 871 | ||
| Dilution | 871 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 871 | ||
| Rate of administration | 872 | ||
| Actions | 872 | ||
| Indications and uses | 872 | ||
| Contraindications | 872 | ||
| Precautions | 872 | ||
| Drug/lab interactions | 873 | ||
| Side effects | 873 | ||
| Antidote | 873 | ||
| Mitoxantrone hydrochloride | 874 | ||
| Usual dose | 874 | ||
| Dose adjustments | 874 | ||
| Dilution | 874 | ||
| Compatibility | 874 | ||
| Rate of administration | 875 | ||
| Actions | 875 | ||
| Indications and uses | 875 | ||
| Contraindications | 875 | ||
| Precautions | 875 | ||
| Drug/lab interactions | 876 | ||
| Side effects | 876 | ||
| Antidote | 877 | ||
| Morphine sulfate | 878 | ||
| Usual dose | 878 | ||
| Pediatric dose | 878 | ||
| Neonatal dose | 878 | ||
| Dose adjustments | 879 | ||
| Dilution | 879 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 879 | ||
| Rate of administration | 880 | ||
| Actions | 880 | ||
| Indications and uses | 880 | ||
| Contraindications | 880 | ||
| Precautions | 880 | ||
| Drug/lab interactions | 881 | ||
| Side effects | 882 | ||
| Antidote | 882 | ||
| Moxifloxacin hydrochloride | 882 | ||
| Usual dose | 882 | ||
| Dose adjustments | 882 | ||
| Dilution | 883 | ||
| Compatibility | 883 | ||
| Rate of administration | 883 | ||
| Actions | 883 | ||
| Indications and uses | 883 | ||
| Contraindications | 884 | ||
| Precautions | 884 | ||
| Drug/lab interactions | 885 | ||
| Side effects | 886 | ||
| Antidote | 886 | ||
| Multivitamin infusion | 887 | ||
| Usual dose | 887 | ||
| Pediatric dose | 887 | ||
| Infuvite pediatric | 887 | ||
| Generic drugs: N | e13 | ||
| Nafcillin sodium | 894 | ||
| Dilution | 895 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 895 | ||
| Rate of administration | 895 | ||
| Actions | 895 | ||
| Indications and uses | 895 | ||
| Contraindications | 895 | ||
| Precautions | 895 | ||
| Drug/lab interactions | 896 | ||
| Side effects | 896 | ||
| Antidote | 897 | ||
| Nalbuphine hydrochloride | 897 | ||
| Usual dose | 897 | ||
| Dose adjustments | 897 | ||
| Dilution | 897 | ||
| Compatibility | 897 | ||
| Rate of administration | 897 | ||
| Actions | 898 | ||
| Indications and uses | 898 | ||
| Contraindications | 898 | ||
| Precautions | 898 | ||
| Drug/lab interactions | 899 | ||
| Side effects | 899 | ||
| Antidote | 899 | ||
| Naloxone hydrochloride | 900 | ||
| Usual dose | 900 | ||
| Pediatric dose | 900 | ||
| Neonatal dose | 900 | ||
| Dilution | 900 | ||
| Compatibility | 900 | ||
| Rate of administration | 901 | ||
| Actions | 901 | ||
| Indications and uses | 901 | ||
| Contraindications | 901 | ||
| Precautions | 901 | ||
| Drug/lab interactions | 901 | ||
| Side effects | 901 | ||
| Antidote | 901 | ||
| Natalizumab | 902 | ||
| Usual dose | 902 | ||
| Dose adjustments | 902 | ||
| Dilution | 902 | ||
| Compatibility | 902 | ||
| Rate of administration | 902 | ||
| Actions | 902 | ||
| Indications and uses | 903 | ||
| Contraindications | 903 | ||
| Precautions | 903 | ||
| Drug/lab interactions | 905 | ||
| Side effects | 905 | ||
| Antidote | 905 | ||
| Necitumumab | 906 | ||
| Usual dose | 906 | ||
| Dose adjustments | 906 | ||
| Dilution | 906 | ||
| Compatibility | 906 | ||
| Rate of administration | 906 | ||
| Actions | 907 | ||
| Indications and uses | 907 | ||
| Contraindications | 907 | ||
| Precautions | 907 | ||
| Drug/lab interactions | 908 | ||
| Side effects | 908 | ||
| Antidote | 908 | ||
| Nelarabine | 909 | ||
| Usual dose | 909 | ||
| Pediatric dose | 909 | ||
| Dose adjustments | 909 | ||
| Dilution | 909 | ||
| Compatibility | 909 | ||
| Rate of administration | 909 | ||
| Actions | 909 | ||
| Indications and uses | 909 | ||
| Contraindications | 909 | ||
| Precautions | 910 | ||
| Drug/lab interactions | 910 | ||
| Side effects | 910 | ||
| Antidote | 911 | ||
| Neostigmine methylsulfate | 912 | ||
| Usual dose | 912 | ||
| Pediatric dose | 912 | ||
| Dose adjustments | 912 | ||
| Dilution | 912 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 912 | ||
| Rate of administration | 912 | ||
| Actions | 912 | ||
| Indications and uses | 913 | ||
| Contraindications | 913 | ||
| Precautions | 913 | ||
| Drug/lab interactions | 914 | ||
| Side effects | 914 | ||
| Antidote | 914 | ||
| Nesiritide | 915 | ||
| Usual dose | 915 | ||
| Dose adjustments | 915 | ||
| Dilution | 915 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 915 | ||
| Rate of administration | 916 | ||
| Actions | 916 | ||
| Indications and uses | 916 | ||
| Contraindications | 917 | ||
| Precautions | 917 | ||
| Drug/lab interactions | 917 | ||
| Side effects | 917 | ||
| Antidote | 918 | ||
| Nicardipine hydrochloride | 918 | ||
| Usual dose | 918 | ||
| Dose adjustments | 918 | ||
| Dilution | 918 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 919 | ||
| Rate of administration | 919 | ||
| Actions | 919 | ||
| Indications and uses | 919 | ||
| Contraindications | 919 | ||
| Precautions | 920 | ||
| Drug/lab interactions | 920 | ||
| Side effects | 920 | ||
| Antidote | 921 | ||
| Nitroglycerin IV | 921 | ||
| Usual dose | 921 | ||
| Pediatric dose | 921 | ||
| Dose adjustments | 921 | ||
| Dilution | 922 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 922 | ||
| Rate of administration | 923 | ||
| Actions | 923 | ||
| Indications and uses | 923 | ||
| Contraindications | 923 | ||
| Precautions | 923 | ||
| Drug/lab interactions | 924 | ||
| Side effects | 924 | ||
| Antidote | 924 | ||
| Nitroprusside sodium | 925 | ||
| Usual dose | 925 | ||
| Pediatric dose | 925 | ||
| Dose adjustments | 925 | ||
| Dilution | 925 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 925 | ||
| Rate of administration | 926 | ||
| Actions | 926 | ||
| Indications and uses | 926 | ||
| Contraindications | 926 | ||
| Precautions | 926 | ||
| Drug/lab interactions | 927 | ||
| Side effects | 927 | ||
| Antidote | 927 | ||
| Nivolumab | 928 | ||
| Usual dose | 928 | ||
| Dose adjustments | 928 | ||
| Dilution | 929 | ||
| Compatibility | 929 | ||
| Rate of administration | 929 | ||
| Actions | 929 | ||
| Indications and uses | 930 | ||
| Contraindications | 930 | ||
| Precautions | 930 | ||
| Drug/lab interactions | 932 | ||
| Side effects | 932 | ||
| Antidote | 933 | ||
| Norepinephrine bitartrate | 933 | ||
| Usual dose | 933 | ||
| Pediatric dose | 933 | ||
| Dose adjustments | 933 | ||
| Dilution | 933 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 934 | ||
| Rate of administration | 934 | ||
| Actions | 934 | ||
| Indications and uses | 934 | ||
| Contraindications | 935 | ||
| Precautions | 935 | ||
| Drug/lab interactions | 935 | ||
| Side effects | 935 | ||
| Antidote | 935 | ||
| Generic drugs: O | e14 | ||
| O | 936 | ||
| Obiltoxaximab | 936 | ||
| Usual dose | 936 | ||
| Pediatric dose | 936 | ||
| Dose adjustments | 936 | ||
| Dilution | 936 | ||
| Compatibility | 937 | ||
| Rate of administration | 937 | ||
| Actions | 937 | ||
| Indications and uses | 937 | ||
| Contraindications | 938 | ||
| Precautions | 938 | ||
| Drug/lab interactions | 938 | ||
| Side effects | 938 | ||
| Antidote | 938 | ||
| Obinutuzumab | 939 | ||
| Usual dose | 939 | ||
| Dose adjustments | 940 | ||
| Dilution | 940 | ||
| Compatibility | 941 | ||
| Rate of administration | 941 | ||
| Actions | 941 | ||
| Indications and uses | 941 | ||
| Contraindications | 941 | ||
| Precautions | 941 | ||
| Drug/lab interactions | 943 | ||
| Side effects | 943 | ||
| Antidote | 943 | ||
| Octreotide acetate | 944 | ||
| Usual dose | 944 | ||
| Pediatric dose | 944 | ||
| Dose adjustments | 944 | ||
| Dilution | 945 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 945 | ||
| Rate of administration | 945 | ||
| Actions | 945 | ||
| Indications and uses | 945 | ||
| Contraindications | 945 | ||
| Precautions | 945 | ||
| Drug/lab interactions | 946 | ||
| Side effects | 947 | ||
| Antidote | 947 | ||
| Ofatumumab | 948 | ||
| Usual dose | 948 | ||
| Dose adjustments | 948 | ||
| Dilution | 949 | ||
| Compatibility | 949 | ||
| Rate of administration | 949 | ||
| Actions | 950 | ||
| Indications and uses | 950 | ||
| Contraindications | 950 | ||
| Precautions | 950 | ||
| Drug/lab interactions | 951 | ||
| Side effects | 952 | ||
| Antidote | 952 | ||
| Ondansetron hydrochloride | 952 | ||
| Usual dose | 952 | ||
| Pediatric dose | 953 | ||
| Dose adjustments | 953 | ||
| Dilution | 953 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 953 | ||
| Rate of administration | 954 | ||
| Actions | 954 | ||
| Indications and uses | 954 | ||
| Contraindications | 954 | ||
| Precautions | 954 | ||
| Drug/lab interactions | 955 | ||
| Side effects | 956 | ||
| Antidote | 956 | ||
| Oritavancin | 957 | ||
| Usual dose | 957 | ||
| Dose adjustments | 957 | ||
| Dilution | 957 | ||
| Compatibility | 957 | ||
| Rate of administration | 957 | ||
| Actions | 957 | ||
| Indications and uses | 957 | ||
| Contraindications | 958 | ||
| Precautions | 958 | ||
| Drug/lab interactions | 958 | ||
| Side effects | 959 | ||
| Antidote | 959 | ||
| Oxaliplatin | 960 | ||
| Usual dose | 960 | ||
| Dose adjustments | 960 | ||
| Dilution | 960 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 961 | ||
| Rate of administration | 961 | ||
| Actions | 961 | ||
| Indications and uses | 961 | ||
| Contraindications | 961 | ||
| Precautions | 962 | ||
| Drug/lab interactions | 963 | ||
| Side effects | 963 | ||
| Antidote | 964 | ||
| Oxymorphone hydrochloride | 964 | ||
| Usual dose | 964 | ||
| Dose adjustments | 964 | ||
| Dilution | 964 | ||
| Compatibility | 965 | ||
| Rate of administration | 965 | ||
| Actions | 965 | ||
| Indications and uses | 965 | ||
| Contraindications | 965 | ||
| Precautions | 965 | ||
| Drug/lab interactions | 966 | ||
| Side effects | 966 | ||
| Antidote | 966 | ||
| Oxytocin injection | 967 | ||
| Usual dose | 967 | ||
| Dilution | 967 | ||
| Compatibility | 967 | ||
| Rate of administration | 967 | ||
| Actions | 967 | ||
| Indications and uses | 968 | ||
| Contraindications | 968 | ||
| Precautions | 968 | ||
| Drug/lab interactions | 968 | ||
| Side effects | 969 | ||
| Antidote | 969 | ||
| Generic drugs: P | e15 | ||
| P | 970 | ||
| Paclitaxel ■ paclitaxel protein-bound particles for injectable suspension (albumin-bound) | 970 | ||
| Usual dose | 970 | ||
| Conventional paclitaxel | 970 | ||
| Generic drugs: Q | e16 | ||
| Q | 1109 | ||
| Quinupristin/dalfopristin | 1109 | ||
| Usual dose | 1109 | ||
| Pediatric dose | 1109 | ||
| Dose adjustments | 1109 | ||
| Dilution | 1109 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 1109 | ||
| Rate of administration | 1110 | ||
| Actions | 1110 | ||
| Indications and uses | 1110 | ||
| Contraindications | 1110 | ||
| Precautions | 1110 | ||
| Drug/lab interactions | 1111 | ||
| Side effects | 1111 | ||
| Antidote | 1111 | ||
| Generic drugs: R | e17 | ||
| R | 1112 | ||
| Ramucirumab | 1112 | ||
| Usual dose | 1112 | ||
| Dose adjustments | 1112 | ||
| Dilution | 1112 | ||
| Compatibility | 1113 | ||
| Rate of administration | 1113 | ||
| Actions | 1113 | ||
| Indications and uses | 1113 | ||
| Contraindications | 1113 | ||
| Precautions | 1113 | ||
| Drug/lab interactions | 1115 | ||
| Side effects | 1115 | ||
| Antidote | 1115 | ||
| Ranitidine | 1116 | ||
| Usual dose | 1116 | ||
| Pediatric dose | 1116 | ||
| Neonatal dose | 1116 | ||
| Dose adjustments | 1116 | ||
| Dilution | 1116 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 1117 | ||
| Rate of administration | 1117 | ||
| Actions | 1118 | ||
| Indications and uses | 1118 | ||
| Contraindications | 1118 | ||
| Precautions | 1118 | ||
| Drug/lab interactions | 1118 | ||
| Side effects | 1119 | ||
| Antidote | 1119 | ||
| Rasburicase | 1119 | ||
| Usual dose | 1119 | ||
| Pediatric dose | 1119 | ||
| Dose adjustments | 1119 | ||
| Dilution | 1119 | ||
| Compatibility | 1120 | ||
| Rate of administration | 1120 | ||
| Actions | 1120 | ||
| Indications and uses | 1120 | ||
| Contraindications | 1120 | ||
| Precautions | 1120 | ||
| Drug/lab interactions | 1121 | ||
| Side effects | 1121 | ||
| Antidote | 1121 | ||
| Raxibacumab | 1122 | ||
| Usual dose | 1122 | ||
| Pediatric dose | 1122 | ||
| Dose adjustments | 1122 | ||
| Dilution | 1122 | ||
| Compatibility | 1123 | ||
| Rate of administration | 1123 | ||
| Actions | 1123 | ||
| Indications and uses | 1123 | ||
| Contraindications | 1123 | ||
| Precautions | 1123 | ||
| Drug/lab interactions | 1123 | ||
| Side effects | 1124 | ||
| Antidote | 1124 | ||
| Reslizumab | 1124 | ||
| Usual dose | 1124 | ||
| Dose adjustments | 1124 | ||
| Dilution | 1124 | ||
| Compatibility | 1124 | ||
| Rate of administration | 1124 | ||
| Actions | 1125 | ||
| Indications and uses | 1125 | ||
| Contraindications | 1125 | ||
| Precautions | 1125 | ||
| Drug/lab interactions | 1126 | ||
| Side effects | 1126 | ||
| Antidote | 1126 | ||
| Reteplase recombinant | 1127 | ||
| Usual dose | 1127 | ||
| Dose adjustments | 1127 | ||
| Dilution | 1127 | ||
| Compatibility | 1127 | ||
| Rate of administration | 1127 | ||
| Actions | 1127 | ||
| Indications and uses | 1128 | ||
| Contraindications | 1128 | ||
| Precautions | 1128 | ||
| Drug/lab interactions | 1129 | ||
| Side effects | 1129 | ||
| Antidote | 1129 | ||
| Rh₀(D) immune globulin intravenous (human) | 1130 | ||
| Usual dose\t(international units [IU]) | 1130 | ||
| Pediatric dose | 1131 | ||
| Dose adjustments\t(international units [IU]) | 1131 | ||
| Dilution\t(international units [IU]) | 1131 | ||
| Compatibility | 1131 | ||
| Rate of administration | 1131 | ||
| Actions\t(international units [IU]) | 1132 | ||
| Indications and uses | 1132 | ||
| Contraindications | 1132 | ||
| Precautions | 1132 | ||
| Drug/lab interactions | 1134 | ||
| Side effects | 1134 | ||
| Antidote | 1134 | ||
| Rifampin | 1135 | ||
| Usual dose | 1135 | ||
| Pediatric dose | 1135 | ||
| Dose adjustments | 1135 | ||
| Dilution | 1135 | ||
| Compatibility | 1135 | ||
| Rate of administration | 1135 | ||
| Actions | 1135 | ||
| Indications and uses | 1135 | ||
| Contraindications | 1136 | ||
| Precautions | 1136 | ||
| Drug/lab interactions | 1137 | ||
| Side effects | 1138 | ||
| Antidote | 1138 | ||
| Rituximab | 1138 | ||
| Usual dose | 1138 | ||
| Dose adjustments | 1139 | ||
| Dilution | 1139 | ||
| Compatibility | 1139 | ||
| Rate of administration | 1139 | ||
| Actions | 1140 | ||
| Indications and uses | 1140 | ||
| Contraindications | 1141 | ||
| Precautions | 1141 | ||
| Drug/lab interactions | 1143 | ||
| Side effects | 1143 | ||
| Antidote | 1144 | ||
| Romidepsin | 1145 | ||
| Usual dose | 1145 | ||
| Dose adjustments | 1145 | ||
| Dilution | 1146 | ||
| Compatibility | 1146 | ||
| Rate of administration | 1146 | ||
| Actions | 1146 | ||
| Indications and uses | 1146 | ||
| Contraindications | 1146 | ||
| Precautions | 1146 | ||
| Drug/lab interactions | 1147 | ||
| Generic drugs: S | e18 | ||
| S | 1148 | ||
| Sargramostim | 1148 | ||
| Usual dose | 1148 | ||
| Dose adjustments | 1149 | ||
| Dilution | 1149 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 1149 | ||
| Rate of administration | 1150 | ||
| Actions | 1150 | ||
| Indications and uses | 1150 | ||
| Contraindications | 1150 | ||
| Precautions | 1150 | ||
| Drug/lab interactions | 1151 | ||
| Side effects | 1151 | ||
| Antidote | 1151 | ||
| Sildenafil * | 1152 | ||
| Usual dose | 1152 | ||
| Dose adjustments | 1152 | ||
| Dilution | 1152 | ||
| Compatibility | 1152 | ||
| Rate of administration | 1152 | ||
| Actions | 1152 | ||
| Indications and uses | 1152 | ||
| Contraindications | 1152 | ||
| Precautions | 1153 | ||
| Drug/lab interactions | 1153 | ||
| Side effects | 1154 | ||
| Antidote | 1154 | ||
| Siltuximab | 1155 | ||
| Usual dose | 1155 | ||
| Dose adjustments | 1155 | ||
| Dilution | 1155 | ||
| Compatibility | 1156 | ||
| Rate of administration | 1156 | ||
| Actions | 1156 | ||
| Indications and uses | 1156 | ||
| Contraindications | 1156 | ||
| Precautions | 1156 | ||
| Drug/lab interactions | 1157 | ||
| Side effects | 1157 | ||
| Antidote | 1157 | ||
| Sipuleucel-T | 1158 | ||
| Usual dose | 1158 | ||
| Dilution | 1158 | ||
| Compatibility | 1158 | ||
| Rate of administration | 1158 | ||
| Actions | 1158 | ||
| Indications and uses | 1159 | ||
| Contraindications | 1159 | ||
| Precautions | 1159 | ||
| Drug/lab interactions | 1159 | ||
| Side effects | 1159 | ||
| Antidote | 1160 | ||
| Sodium acetate | 1160 | ||
| Usual dose | 1160 | ||
| Dose adjustments | 1160 | ||
| Dilution | 1160 | ||
| Compatibility | 1160 | ||
| Rate of administration | 1160 | ||
| Actions | 1160 | ||
| Indications and uses | 1160 | ||
| Contraindications | 1161 | ||
| Precautions | 1161 | ||
| Drug/lab interactions | 1161 | ||
| Side effects | 1161 | ||
| Antidote | 1161 | ||
| Sodium bicarbonate | 1162 | ||
| Usual dose | 1162 | ||
| Pediatric dose | 1162 | ||
| Dilution | 1162 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 1162 | ||
| Rate of administration | 1163 | ||
| Actions | 1163 | ||
| Indications and uses | 1163 | ||
| Contraindications | 1163 | ||
| Precautions | 1163 | ||
| Drug/lab interactions | 1164 | ||
| Side effects | 1164 | ||
| Antidote | 1164 | ||
| Sodium chloride | 1164 | ||
| Usual dose | 1164 | ||
| Dose adjustments | 1165 | ||
| Dilution | 1165 | ||
| Compatibility | 1165 | ||
| Rate of administration | 1165 | ||
| Actions | 1165 | ||
| Indications and uses | 1166 | ||
| Contraindications | 1166 | ||
| Precautions | 1166 | ||
| Drug/lab interactions | 1167 | ||
| Side effects | 1167 | ||
| Antidote | 1167 | ||
| Sodium ferric gluconate complex | 1167 | ||
| Usual dose | 1167 | ||
| Pediatric dose | 1167 | ||
| Dose adjustments | 1167 | ||
| Dilution | 1167 | ||
| Compatibility | 1168 | ||
| Rate of administration | 1168 | ||
| Actions | 1168 | ||
| Indications and uses | 1168 | ||
| Contraindications | 1168 | ||
| Precautions | 1168 | ||
| Drug/lab interactions | 1169 | ||
| Side effects | 1169 | ||
| Antidote | 1169 | ||
| Sodium phenylacetate and sodium benzoate | 1170 | ||
| Usual dose | 1170 | ||
| Dose adjustments | 1171 | ||
| Dilution | 1171 | ||
| Compatibility | 1171 | ||
| Rate of administration | 1171 | ||
| Actions | 1172 | ||
| Indications and uses | 1172 | ||
| Contraindications | 1172 | ||
| Precautions | 1172 | ||
| Drug/lab interactions | 1173 | ||
| Side effects | 1174 | ||
| Antidote | 1174 | ||
| Sotalol hydrochloride | 1175 | ||
| Usual dose | 1175 | ||
| Dose adjustments | 1175 | ||
| Dilution | 1175 | ||
| Compatibility | 1176 | ||
| Rate of administration | 1176 | ||
| Actions | 1176 | ||
| Indications and uses | 1176 | ||
| Contraindications | 1176 | ||
| Precautions | 1176 | ||
| Drug/lab interactions | 1177 | ||
| Side effects | 1178 | ||
| Antidote | 1178 | ||
| Streptozocin | 1179 | ||
| Usual dose | 1179 | ||
| Dose adjustments | 1179 | ||
| Dilution | 1179 | ||
| Compatibility | 1179 | ||
| Rate of administration | 1179 | ||
| Actions | 1179 | ||
| Indications and uses | 1179 | ||
| Contraindications | 1179 | ||
| Precautions | 1179 | ||
| Drug/lab interactions | 1180 | ||
| Side effects | 1180 | ||
| Antidote | 1180 | ||
| Sugammadex | 1181 | ||
| Usual dose | 1181 | ||
| Dose adjustments | 1181 | ||
| Dilution | 1181 | ||
| Compatibility | 1181 | ||
| Rate of administration | 1181 | ||
| Actions | 1182 | ||
| Indications and uses | 1182 | ||
| Contraindications | 1182 | ||
| Precautions | 1182 | ||
| Drug/lab interactions | 1183 | ||
| Side effects | 1183 | ||
| Antidote | 1184 | ||
| Sulfamethoxazole and trimethoprim | 1184 | ||
| Usual dose | 1184 | ||
| Dose adjustments | 1184 | ||
| Dilution | 1184 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 1184 | ||
| Rate of administration | 1185 | ||
| Actions | 1185 | ||
| Indications and uses | 1185 | ||
| Contraindications | 1185 | ||
| Precautions | 1185 | ||
| Drug/lab interactions | 1186 | ||
| Side effects | 1186 | ||
| Antidote | 1186 | ||
| Generic drugs: T | e19 | ||
| T | 1187 | ||
| Tacrolimus | 1187 | ||
| Usual dose | 1187 | ||
| Pediatric dose | 1187 | ||
| Dose adjustments | 1187 | ||
| Dilution | 1187 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 1188 | ||
| Rate of administration | 1188 | ||
| Actions | 1188 | ||
| Indications and uses | 1188 | ||
| Contraindications | 1189 | ||
| Precautions | 1189 | ||
| Drug/lab interactions | 1191 | ||
| Side effects | 1191 | ||
| Antidote | 1192 | ||
| Taliglucerase alfa | 1193 | ||
| Usual dose | 1193 | ||
| Dose adjustments | 1193 | ||
| Dilution | 1193 | ||
| Compatibility | 1193 | ||
| Rate of administration | 1193 | ||
| Actions | 1194 | ||
| Indications and uses | 1194 | ||
| Contraindications | 1194 | ||
| Precautions | 1194 | ||
| Drug/lab interactions | 1195 | ||
| Side effects | 1195 | ||
| Antidote | 1195 | ||
| Tedizolid phosphate | 1196 | ||
| Usual dose | 1196 | ||
| Dose adjustments | 1196 | ||
| Dilution | 1196 | ||
| Compatibility | 1196 | ||
| Rate of administration | 1196 | ||
| Actions | 1196 | ||
| Indications and uses | 1197 | ||
| Contraindications | 1197 | ||
| Precautions | 1197 | ||
| Drug/lab interactions | 1197 | ||
| Side effects | 1197 | ||
| Antidote | 1198 | ||
| Telavancin | 1198 | ||
| Usual dose | 1198 | ||
| Dose adjustments | 1198 | ||
| Dilution | 1198 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 1199 | ||
| Rate of administration | 1199 | ||
| Actions | 1199 | ||
| Indications and uses | 1199 | ||
| Contraindications | 1199 | ||
| Precautions | 1199 | ||
| Drug/lab interactions | 1201 | ||
| Side effects | 1201 | ||
| Antidote | 1201 | ||
| Temozolomide | 1202 | ||
| Usual dose | 1202 | ||
| Dose adjustments | 1203 | ||
| Dilution | 1204 | ||
| Compatibility | 1204 | ||
| Rate of administration | 1204 | ||
| Actions | 1204 | ||
| Indications and uses | 1205 | ||
| Contraindications | 1205 | ||
| Precautions | 1205 | ||
| Drug/lab interactions | 1206 | ||
| Side effects | 1206 | ||
| Antidote | 1207 | ||
| Temsirolimus | 1207 | ||
| Usual dose | 1207 | ||
| Dose adjustments | 1207 | ||
| Dilution | 1207 | ||
| Compatibility | 1208 | ||
| Rate of administration | 1208 | ||
| Actions | 1208 | ||
| Indications and uses | 1208 | ||
| Contraindications | 1208 | ||
| Precautions | 1208 | ||
| Drug/lab interactions | 1210 | ||
| Side effects | 1210 | ||
| Antidote | 1211 | ||
| Tenecteplase | 1211 | ||
| Usual dose | 1211 | ||
| Dose adjustments | 1211 | ||
| Dilution | 1211 | ||
| Compatibility | 1212 | ||
| Rate of administration | 1212 | ||
| Actions | 1212 | ||
| Indications and uses | 1212 | ||
| Contraindications | 1212 | ||
| Precautions | 1212 | ||
| Drug/lab interactions | 1213 | ||
| Side effects | 1213 | ||
| Antidote | 1214 | ||
| Teniposide | 1214 | ||
| Usual dose | 1214 | ||
| Pediatric dose | 1214 | ||
| Dose adjustments | 1214 | ||
| Dilution | 1214 | ||
| Compatibility | 1215 | ||
| Rate of administration | 1215 | ||
| Actions | 1215 | ||
| Indications and uses | 1216 | ||
| Contraindications | 1216 | ||
| Precautions | 1216 | ||
| Drug/lab interactions | 1217 | ||
| Side effects | 1217 | ||
| Antidote | 1217 | ||
| Thiamine hydrochloride | 1218 | ||
| Usual dose | 1218 | ||
| Pediatric dose | 1218 | ||
| Dilution | 1218 | ||
| Compatibility | 1218 | ||
| Rate of administration | 1218 | ||
| Actions | 1218 | ||
| Indications and uses | 1218 | ||
| Contraindications | 1219 | ||
| Precautions | 1219 | ||
| Side effects | 1219 | ||
| Antidote | 1219 | ||
| Thiotepa | 1219 | ||
| Usual dose | 1219 | ||
| Dose adjustments | 1219 | ||
| Dilution | 1219 | ||
| Compatibility | 1220 | ||
| Rate of administration | 1220 | ||
| Actions | 1220 | ||
| Indications and uses | 1220 | ||
| Contraindications | 1220 | ||
| Precautions | 1220 | ||
| Drug/lab interactions | 1221 | ||
| Side effects | 1221 | ||
| Antidote | 1221 | ||
| Tigecycline for injection | 1222 | ||
| Usual dose | 1222 | ||
| Dose adjustments | 1222 | ||
| Dilution | 1222 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 1222 | ||
| Rate of administration | 1222 | ||
| Actions | 1223 | ||
| Indications and uses | 1223 | ||
| Contraindications | 1223 | ||
| Precautions | 1223 | ||
| Drug/lab interactions | 1224 | ||
| Side effects | 1224 | ||
| Antidote | 1224 | ||
| Tirofiban hydrochloride | 1225 | ||
| Usual dose | 1225 | ||
| Dose adjustments | 1225 | ||
| Dilution | 1225 | ||
| Compatibility | 1225 | ||
| Rate of administration | 1225 | ||
| Actions | 1226 | ||
| Indications and uses | 1226 | ||
| Contraindications | 1226 | ||
| Precautions | 1226 | ||
| Drug/lab interactions | 1227 | ||
| Side effects | 1227 | ||
| Antidote | 1227 | ||
| Tobramycin sulfate | 1228 | ||
| Usual dose | 1228 | ||
| Pediatric dose | 1228 | ||
| Neonatal dose | 1228 | ||
| Dose adjustments | 1228 | ||
| Dilution | 1229 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 1229 | ||
| Rate of administration | 1229 | ||
| Actions | 1229 | ||
| Indications and uses | 1229 | ||
| Contraindications | 1229 | ||
| Precautions | 1230 | ||
| Drug/lab interactions | 1230 | ||
| Side effects | 1231 | ||
| Antidote | 1231 | ||
| Tocilizumab | 1232 | ||
| Usual dose | 1232 | ||
| Dose adjustments | 1232 | ||
| Dilution | 1233 | ||
| Compatibility | 1233 | ||
| Rate of administration | 1233 | ||
| Actions | 1233 | ||
| Indications and uses | 1234 | ||
| Contraindications | 1234 | ||
| Precautions | 1234 | ||
| Drug/lab interactions | 1235 | ||
| Side effects | 1236 | ||
| Antidote | 1236 | ||
| Topotecan hydrochloride | 1237 | ||
| Usual dose | 1237 | ||
| Dose adjustments | 1237 | ||
| Dilution | 1237 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 1237 | ||
| Rate of administration | 1238 | ||
| Actions | 1238 | ||
| Indications and uses | 1238 | ||
| Contraindications | 1238 | ||
| Precautions | 1238 | ||
| Drug/lab interactions | 1239 | ||
| Side effects | 1239 | ||
| Antidote | 1239 | ||
| Torsemide injection | 1240 | ||
| Usual dose | 1240 | ||
| Dose adjustments | 1240 | ||
| Dilution | 1240 | ||
| Compatibility | 1240 | ||
| Rate of administration | 1240 | ||
| Actions | 1240 | ||
| Indications and uses | 1241 | ||
| Contraindications | 1241 | ||
| Precautions | 1241 | ||
| Drug/lab interactions | 1241 | ||
| Side effects | 1242 | ||
| Antidote | 1242 | ||
| Trabectedin | 1243 | ||
| Usual dose | 1243 | ||
| Dose adjustments | 1243 | ||
| Dilution | 1244 | ||
| Compatibility | 1244 | ||
| Rate of administration | 1244 | ||
| Actions | 1244 | ||
| Indications and uses | 1244 | ||
| Contraindications | 1244 | ||
| Precautions | 1244 | ||
| Drug/lab interactions | 1245 | ||
| Side effects | 1246 | ||
| Antidote | 1246 | ||
| Tranexamic acid | 1246 | ||
| Usual dose | 1246 | ||
| Dose adjustments | 1247 | ||
| Dilution | 1247 | ||
| Compatibility | 1247 | ||
| Rate of administration | 1247 | ||
| Actions | 1247 | ||
| Indications and uses | 1247 | ||
| Contraindications | 1247 | ||
| Precautions | 1247 | ||
| Drug/lab interactions | 1248 | ||
| Side effects | 1248 | ||
| Antidote | 1248 | ||
| Trastuzumab | 1248 | ||
| Usual dose | 1248 | ||
| Dose adjustments | 1249 | ||
| Dilution | 1249 | ||
| Compatibility | 1250 | ||
| Rate of administration | 1250 | ||
| Actions | 1250 | ||
| Indications and uses | 1250 | ||
| Contraindications | 1250 | ||
| Precautions | 1250 | ||
| Drug/lab interactions | 1252 | ||
| Side effects | 1252 | ||
| Antidote | 1252 | ||
| Tromethamine | 1253 | ||
| Usual dose | 1253 | ||
| Pediatric dose | 1253 | ||
| Dose adjustments | 1253 | ||
| Dilution | 1253 | ||
| Compatibility | 1253 | ||
| Rate of administration | 1253 | ||
| Actions | 1254 | ||
| Indications and uses | 1254 | ||
| Contraindications | 1254 | ||
| Precautions | 1254 | ||
| Drug/lab interactions | 1254 | ||
| Side effects | 1254 | ||
| Antidote | 1254 | ||
| Generic drugs: V | e20 | ||
| V | 1255 | ||
| Vaccinia immune globulin intravenous (human) | 1255 | ||
| Usual dose | 1255 | ||
| Dose adjustments | 1255 | ||
| Dilution | 1255 | ||
| Compatibility | 1255 | ||
| Rate of administration | 1255 | ||
| Actions | 1255 | ||
| Indications and uses | 1256 | ||
| Contraindications | 1256 | ||
| Precautions | 1256 | ||
| Drug/lab interactions | 1257 | ||
| Side effects | 1257 | ||
| Antidote | 1257 | ||
| Valproate sodium | 1258 | ||
| Usual dose | 1258 | ||
| Pediatric dose | 1258 | ||
| Dose adjustments | 1258 | ||
| Dilution | 1258 | ||
| Compatibility | 1258 | ||
| Rate of administration | 1259 | ||
| Actions | 1259 | ||
| Indications and uses | 1259 | ||
| Contraindications | 1259 | ||
| Precautions | 1259 | ||
| Drug/lab interactions | 1262 | ||
| Side effects | 1263 | ||
| Antidote | 1263 | ||
| Vancomycin hydrochloride | 1264 | ||
| Usual dose | 1264 | ||
| Pediatric dose | 1264 | ||
| Neonatal dose | 1265 | ||
| Dose adjustments | 1265 | ||
| Dilution | 1265 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 1265 | ||
| Rate of administration | 1266 | ||
| Actions | 1266 | ||
| Indications and uses | 1266 | ||
| Contraindications | 1267 | ||
| Precautions | 1267 | ||
| Drug/lab interactions | 1267 | ||
| Side effects | 1268 | ||
| Antidote | 1268 | ||
| Vasopressin injection | 1268 | ||
| Usual dose | 1268 | ||
| All IV doses and uses are unlabeled. | 1268 | ||
| Treatment of shock-resistant VF or pulseless VT during cardiac arrest in adult patients: | 1268 | ||
| Hemodynamic support during vasodilatory shock (e.g., septic shock): | 1268 | ||
| GI hemorrhage: | 1268 | ||
| Pediatric dose | 1268 | ||
| Dilution | 1269 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 1269 | ||
| Rate of administration | 1269 | ||
| Actions | 1269 | ||
| Indications and uses | 1269 | ||
| Contraindications | 1269 | ||
| Precautions | 1270 | ||
| Drug/lab interactions | 1270 | ||
| Side effects | 1270 | ||
| Antidote | 1270 | ||
| Vecuronium bromide | 1271 | ||
| Usual dose | 1271 | ||
| Pediatric dose | 1271 | ||
| Dose adjustments | 1271 | ||
| Dilution | 1271 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 1271 | ||
| Rate of administration | 1272 | ||
| Actions | 1272 | ||
| Indications and uses | 1272 | ||
| Contraindications | 1272 | ||
| Precautions | 1273 | ||
| Drug/lab interactions | 1273 | ||
| Side effects | 1273 | ||
| Antidote | 1273 | ||
| Vedolizumab | 1274 | ||
| Usual dose | 1274 | ||
| Dose adjustments | 1274 | ||
| Dilution | 1274 | ||
| Compatibility | 1274 | ||
| Rate of administration | 1274 | ||
| Actions | 1274 | ||
| Indications and uses | 1275 | ||
| Contraindications | 1275 | ||
| Precautions | 1275 | ||
| Drug/lab interactions | 1276 | ||
| Side effects | 1276 | ||
| Antidote | 1276 | ||
| Verapamil hydrochloride | 1276 | ||
| Usual dose | 1276 | ||
| Pediatric dose | 1276 | ||
| Dose adjustments | 1276 | ||
| Dilution | 1277 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 1277 | ||
| Rate of administration | 1277 | ||
| Actions | 1277 | ||
| Indications and uses | 1277 | ||
| Contraindications | 1278 | ||
| Precautions | 1278 | ||
| Drug/lab interactions | 1278 | ||
| Side effects | 1279 | ||
| Antidote | 1279 | ||
| Verteporfin | 1280 | ||
| Usual dose | 1280 | ||
| Dose adjustments | 1280 | ||
| Dilution | 1280 | ||
| Compatibility | 1280 | ||
| Rate of administration | 1280 | ||
| Actions | 1281 | ||
| Indications and uses | 1281 | ||
| Contraindications | 1281 | ||
| Precautions | 1281 | ||
| Drug/lab interactions | 1282 | ||
| Side effects | 1282 | ||
| Antidote | 1283 | ||
| Vinblastine sulfate | 1283 | ||
| Usual dose | 1283 | ||
| Pediatric dose | 1283 | ||
| Dose adjustments | 1283 | ||
| Dilution | 1283 | ||
| Compatibility | 1284 | ||
| Rate of administration | 1284 | ||
| Actions | 1284 | ||
| Indications and uses | 1284 | ||
| Contraindications | 1284 | ||
| Precautions | 1284 | ||
| Drug/lab interactions | 1285 | ||
| Side effects | 1285 | ||
| Antidote | 1285 | ||
| Vincristine sulfate vincristine sulfate liposome injection | 1286 | ||
| Usual dose | 1285 | ||
| Conventional vincristine | 1285 | ||
| W | e21 | ||
| Warfarin sodium | 1310 | ||
| Usual dose | 1310 | ||
| Pediatric dose | 1310 | ||
| Dose adjustments | 1310 | ||
| Dilution | 1311 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 1311 | ||
| Rate of administration | 1311 | ||
| Actions | 1311 | ||
| Indications and uses | 1311 | ||
| Contraindications | 1311 | ||
| Precautions | 1311 | ||
| Drug/lab interactions | 1313 | ||
| Side effects | 1314 | ||
| Antidote | 1315 | ||
| Generic drugs: Z | e22 | ||
| Z | 1316 | ||
| Zidovudine | 1316 | ||
| Usual dose | 1316 | ||
| Pediatric dose | 1316 | ||
| Neonatal dose | 1316 | ||
| Dose adjustments | 1316 | ||
| Dilution | 1316 | ||
| Compatibility\t(underline indicates conflicting compatibility information) | 1317 | ||
| Rate of administration | 1317 | ||
| Actions | 1317 | ||
| Indications and uses | 1317 | ||
| Contraindications | 1317 | ||
| Precautions | 1317 | ||
| Drug/lab interactions | 1319 | ||
| Side effects | 1319 | ||
| Antidote | 1319 | ||
| Ziv-aflibercept | 1320 | ||
| Usual dose | 1320 | ||
| Dose adjustments | 1320 | ||
| Dilution | 1320 | ||
| Compatibility | 1321 | ||
| Rate of administration | 1321 | ||
| Actions | 1321 | ||
| Indications and uses | 1321 | ||
| Contraindications | 1321 | ||
| Precautions | 1321 | ||
| Drug/lab interactions | 1322 | ||
| Side effects | 1322 | ||
| Antidote | 1322 | ||
| Zoledronic acid | 1323 | ||
| Usual dose\t(international units [IU]) | 1323 | ||
| Appendix A Recommendations for the safe use and handling of cytotoxic drugs | 1331 | ||
| Appendix B FDA pregnancy categories | 1332 | ||
| Appendix D Information for patients receiving immunosuppressive agents | 1333 | ||
| Appendix E Recently approved drugs | 1334 | ||
| Brivaracetam | 1334 | ||
| Usual dose | 1334 | ||
| Dose adjustments | 1334 | ||
| Dilution | 1334 | ||
| Compatibility | 1334 | ||
| Rate of administration | 1334 | ||
| Actions | 1334 | ||
| Indications and uses | 1334 | ||
| Contraindications | 1335 | ||
| Precautions | 1335 | ||
| Drug/lab interactions | 1335 | ||
| Side effects | 1336 | ||
| Antidote | 1336 | ||
| Crotalidae immune F(ab⁹)₂ (equine) | 1336 | ||
| Usual dose | 1336 | ||
| Dose adjustments | 1336 | ||
| Dilution | 1336 | ||
| Compatibility | 1337 | ||
| Rate of administration | 1337 | ||
| Actions | 1337 | ||
| Indications and uses | 1337 | ||
| Contraindications | 1337 | ||
| Precautions | 1337 | ||
| Drug/lab interactions | 1338 | ||
| Side effects | 1338 | ||
| Antidote | 1338 | ||
| Defibrotide | 1338 | ||
| Usual dose | 1338 | ||
| Dose adjustments | 1338 | ||
| Dilution | 1339 | ||
| Compatibility | 1339 | ||
| Rate of administration | 1339 | ||
| Actions | 1339 | ||
| Indications and uses | 1339 | ||
| Contraindications | 1340 | ||
| Precautions | 1340 | ||
| Drug/lab interactions | 1340 | ||
| Side effects | 1340 | ||
| Antidote | 1340 | ||
| Index | 1341 | ||
| A | 1341 | ||
| B | 1348 | ||
| C | 1348 | ||
| D | 1350 | ||
| E | 1351 | ||
| F | 1352 | ||
| G | 1353 | ||
| H | 1353 | ||
| I | 1354 | ||
| J | 1355 | ||
| K | 1355 | ||
| L | 1355 | ||
| M | 1356 | ||
| N | 1357 | ||
| O | 1358 | ||
| P | 1358 | ||
| Q | 1360 | ||
| R | 1360 | ||
| S | 1360 | ||
| T | 1361 | ||
| U | 1362 | ||
| V | 1362 | ||
| W | 1363 | ||
| X | 1363 | ||
| Y | 1363 | ||
| Z | 1363 | ||
| Solution compatibility chart | ibc |